Power3 Medical Products, Inc. (OTC:PWRM)
Power3 Medical uses its Proteomic-based platform to analyze breast cancer at the protein level.
To date, they have identified over 120 distinct biomarkers relating to breast cancer.
In collaboration with a major research institute in Houston Texas, the Company has developed the Early Detection Breast Cancer Test, BC-SeraPro.
This test indicates, years prior to mammography, whether the patient has an early indication for breast cancer and if they require more testing or treatment.
Power3 believes the BC-SeraPro Test™ will become the standard precursor to the mammogram.
- In 2003, the breast cancer diagnostic market totaled $7 billion, which included $4.2 billion in mammograms and most of the remaining $2.8 billion in biopsy procedures.
- The global mammogram market is estimated at approximately $10 billion by the World Health Organization(WHO) and is growing especially in Asia where the incidences of breast cancer occur more frequently and at a younger age.
- Breast cancer is the second leading cause of cancer deaths in women today.
As a New technology for early detection, minimally-invasive BC-SeraPro™ Test from Power3 should participate favorably in the aforementioned mammogram market and has the potential to capture a significant portion of the pre-mammography early detection market. ( Read More http://crwepicks.com/?p=14938 )